Investor Presentaiton

IBI-310 (CTLA-4) Development Plan Overview Leading CTLA-4 Antibody at Multiple Pivotal Studies in China Phase 1a/1b Safety Data (N=27) Part B+C (1b): IBI-310+ sintilimab IBI-310 + Sintilimab Development Program Overview • Melanoma Phase 3 trial in adjuvant setting (First patient dosed in China in Apr 2020) Cervical Phase 2 trial in 2nd line and above (First patient dosed in China in Dec 2020) Melanoma subtypes Part A (1a): IBI-310 N=10 N=17 Mucosal Acral 6 (60%) 5 (31.3%) Clinical 3 (30%) 2 (12.5%) Non-chronic sun damaged progress 1 (10%) 9 (56.3%) HCC chronic sun damaged 0 1 (5.9%) Part B+C (1b): IBI-310 + Part A (1a): IBI-310 N=10 sintilimab N=17 Phase 3 trial in 1st line (First patient dosed in China in Feb 2021) No DLT DLT No DLT AE > grade 3 No AEs of grade 3 One AE of grade 3: AST increased 2021 plan • Disclosed at ASCO 2020 Abstract - Cervical To complete patient enrolment for cervical cancer by 2021 Melanoma To release the Phase 1 study data of IBI-310 in melanoma CTLA-4 is one of the few validated IO targets worldwide. IBI-310 has shown good safety profile in Phase 1 studies and progressed into registrational trials for multiple indications. Innovent Confidential Copyright©2021 Innovent Biologics 27

View entire presentation